Trials / Completed
CompletedNCT01005823
A Safety, Tolerability and Pharmacokinetic Study of LEO 29102 in Subjects With Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of 7 days treatment with LEO 29102 in adult patients with atopic dermatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 29102 cream | Twice daily application for 7 days |
| DRUG | LEO 29102 placebo cream | LEO 29102 placebo cream |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2009-11-02
- Last updated
- 2025-02-24
Locations
1 site across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT01005823. Inclusion in this directory is not an endorsement.